【摘要】 探讨奥利司他(orlistat)在治疗肥胖伴非酒精性脂肪性肝病(NAFLD)中的作用。选择体重指数(BM I)在25和32之间,伴有肝功能异常的NAFLD患者30例,给予奥利司他120mg,日三次口服,治疗24周。治疗结束后,所有患者的体重、BM I、腰围、腰臀比及血压明显下降(P值均<0.001);肝功能中ALT、AST、GGT、Tch、TG及IR与治疗前相比有明显改善(P值均<0.001);肝脏CT密度值及肝/脾CT密度比值均显著增加(P值均<0.001)。奥利司他可有效地减少NAFLD患者肝脏内脂肪沉积,改善肝功能和相关代谢综合征,可作为肥胖伴NAFLD的药物治疗选择。更多还原

【Abstract】 To evaluate the efficacy of orlistat in the treatment of obesity with non-alcoholic fatty liver disease.Orlistat 120mg,three times per day for a couse of 24 weeks,were given to the 30 cases non-alcoholic fatty liver disease(NAFLD) patients whose body mass index(BMI) were between 25 and 32.After 24 weeks treatment,mean weight、BMI、waist and waist/hip ratio(WHR) and blood pressure was significantly decreased(P<0.001);Liver functions(ALT、AST、GGT、TG and Tch) and IR was significantly decreased(P<0.001);The liver density value by CT scan and liver/spleen ratio by CT scan was significantly increased(P<0.001).Orlistat can decrease the fat deposit on liver of NAFLD,improve the liver function and metabolic syndrome.It is a drug choice for obese patients with NAFLD.更多还原